Century Therapeutics, Inc.
IPSC
Rank in Stocks
#14378
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering... Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments. In addition to its lead candidate, the company's robust pipeline features several other therapeutic assets: CNTY-103: A CAR-iNK candidate aimed at CD133 + EGFR for recurrent glioblastoma. CNTY-102: A CAR-iT therapy targeting CD19 + CD79b, intended for relapsed or refractory B-cell lymphoma and other B-cell cancers. CNTY-104: A multi-specific CAR-iT or CAR-iNK candidate in development for acute myeloid leukemia. CNTY-106: Another multi-specific CAR-iNK or CAR-iT candidate for multiple myeloma. Established in 2018, Century Therapeutics, Inc. is based in Philadelphia, Pennsylvania.
Share Price
$1.81
Last synced: 2026-11-09
Market Cap
$327.75M
Change (1 day)
7.74%
Change (1 year)
221.32%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Century Therapeutics, Inc. (IPSC)
Category
Healthcare
EPS for Century Therapeutics, Inc. (IPSC)
EPS as of June 2026 TTM: $-1.04
According to Century Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-1.04. At the end of 2025 the company had an EPS of $-0.11, an increase over its 2024 EPS of $-1.61.
EPS history for Century Therapeutics, Inc. from 2019 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.04 | 845.45% |
| 2025 | $-0.11 | -93.17% |
| 2024 | $-1.61 | -30.00% |
| 2023 | $-2.30 | 1.32% |
| 2022 | $-2.27 | 30.46% |
| 2021 | $-1.74 | 74.00% |
| 2020 | $-1.00 | -77.73% |
| 2019 | $-4.49 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -1,605.77% |
US
|
|
| $-7.07 | 579.81% |
US
|
|
| $-5.29 | 408.65% |
AU
|
|
| $12.88 | -1,338.47% |
BE
|
|
| $21.56 | -2,173.08% |
NL
|
Questions about Century Therapeutics, Inc.'s earnings per share (EPS)
What is Century Therapeutics, Inc.'s earnings per share (EPS)?
Century Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-1.04, as of Jun 2026.
What was Century Therapeutics, Inc.'s earnings per share (EPS) in 2025?
In 2025, Century Therapeutics, Inc.'s earnings per share (EPS) was $-0.11, compared with $-1.61 in 2024.
How has Century Therapeutics, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Century Therapeutics, Inc.'s earnings per share (EPS) was highest in 2025 ($-0.11) and lowest in 2023 ($-2.30).
How does Century Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
Century Therapeutics, Inc.'s earnings per share (EPS) ($-1.04) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.